Search Results

There are 17108 results for: content related to: Twelve-month safety of entacapone in patients with Parkinson’s disease

  1. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease

    Intervention Review

    The Cochrane Library

    Katherine Deane, Sybille Spieker and Carl E Clarke

    Published Online : 18 OCT 2004, DOI: 10.1002/14651858.CD004554.pub2

  2. Catechol-O-Methyltransferase (COMT) Inhibitors in Parkinson's Disease

    Journal of the American Geriatrics Society

    Volume 48, Issue 6, June 2000, Pages: 692–698, Cheryl Waters

    Version of Record online : 27 APR 2015, DOI: 10.1111/j.1532-5415.2000.tb04732.x

  3. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

    Movement Disorders

    Volume 26, Issue S3, October 2011, Pages: S2–S41, Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz and Cristina Sampaio

    Version of Record online : 21 OCT 2011, DOI: 10.1002/mds.23829

  4. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)

    Acta Neurologica Scandinavica

    Volume 105, Issue 4, April 2002, Pages: 245–255, W. H. Poewe, G. Deuschl, A. Gordin, E.-R. Kultalahti, M. Leinonen and the Celomen Study Group

    Version of Record online : 3 APR 2002, DOI: 10.1034/j.1600-0404.2002.1o174.x

  5. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications

    Intervention Review

    The Cochrane Library

    Rebecca Stowe, Natalie Ives, Carl E Clarke, Katherine Deane, van Hilten, Keith Wheatley, Richard Gray, Kelly Handley and Alex Furmston

    Published Online : 7 JUL 2010, DOI: 10.1002/14651858.CD007166.pub2

  6. Development of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to entacapone low bioavailability

    Biopharmaceutics & Drug Disposition

    Volume 36, Issue 9, December 2015, Pages: 587–602, Saeed Alqahtani and Amal Kaddoumi

    Version of Record online : 24 DEC 2015, DOI: 10.1002/bdd.1986

  7. Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients

    Movement Disorders

    Volume 22, Issue 1, January 2007, Pages: 75–80, Yoshikuni Mizuno, Ichiro Kanazawa, Sadako Kuno, Nobuo Yanagisawa, Mitsutoshi Yamamoto and Tomoyoshi Kondo

    Version of Record online : 8 NOV 2006, DOI: 10.1002/mds.21218

  8. Pooled analysis of phase III with entacapone in Parkinson's disease

    Acta Neurologica Scandinavica

    Volume 130, Issue 4, October 2014, Pages: 239–247, M. Kuoppamäki, M. Vahteristo, J. Ellmén and K. Kieburtz

    Version of Record online : 3 SEP 2014, DOI: 10.1111/ane.12278

  9. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease

    European Journal of Neurology

    Volume 10, Issue 2, March 2003, Pages: 137–146, J. P. Larsen, J. Worm-Petersen, Å. Sidén, A. Gordin, K. Reinikainen, M. Leinonen and the NOMESAFE Study Group

    Version of Record online : 26 FEB 2003, DOI: 10.1046/j.1468-1331.2003.00559.x

  10. You have free access to this content
    Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease

    CNS Neuroscience & Therapeutics

    Volume 14, Issue 1, Spring 2008, Pages: 83–93, Andrew J. Lees

    Version of Record online : 14 MAR 2008, DOI: 10.1111/j.1527-3458.2007.00035.x

  11. Catechol-O-methyltransferase inhibitors: Clinical potential in the treatment of Parkinson's disease

    Drug Development Research

    Volume 42, Issue 1, September 1997, Pages: 1–25, Jasper Dingemanse

    Version of Record online : 6 DEC 1998, DOI: 10.1002/(SICI)1098-2299(199709)42:1<1::AID-DDR1>3.0.CO;2-I

  12. Bimodal administration of entacapone in Parkinson’s disease patients improves motor control

    European Journal of Neurology

    Volume 15, Issue 3, March 2008, Pages: 268–273, L. Bet, S. R. Bareggi, F. Pacei, G. Bondiolotti, G. Meola and A. H. V Schapira

    Version of Record online : 14 FEB 2008, DOI: 10.1111/j.1468-1331.2007.02043.x

  13. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: A randomized crossover clinical trial

    Annals of Neurology

    Volume 69, Issue 1, January 2011, Pages: 111–118, Jean-Christophe Corvol, Cécilia Bonnet, Fanny Charbonnier-Beaupel, Anne-Marie Bonnet, Marie-Hélène Fiévet, Agnès Bellanger, Emmanuel Roze, Gayané Meliksetyan, Mouna Ben Djebara, Andreas Hartmann, Lucette Lacomblez, Cédric Vrignaud, Noël Zahr, Yves Agid, Jean Costentin, Jean-Sébastien Hulot and Marie Vidailhet

    Version of Record online : 28 JAN 2011, DOI: 10.1002/ana.22155

  14. You have free access to this content
    Entacapone promotes cAMP-dependent colonic Cl secretion in rats

    Neurogastroenterology & Motility

    Volume 23, Issue 7, July 2011, Pages: 657–e277, L.-S. Li, L.-F. Zheng, J.-D. Xu, T. Ji, H. Guo, X.-F. Li, Y. Li, Y. Zhang and J.-X. Zhu

    Version of Record online : 19 APR 2011, DOI: 10.1111/j.1365-2982.2011.01715.x

  15. The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF

    Movement Disorders

    Volume 25, Issue 3, 15 February 2010, Pages: 363–367, Maria Nord, Peter Zsigmond, Anita Kullman, Kerstin Årstrand and Nil Dizdar

    Version of Record online : 13 JAN 2010, DOI: 10.1002/mds.22613

  16. You have free access to this content
    Cost-Effectiveness Analysis of Entacapone in Parkinson's Disease: A Markov Process Analysis

    Value in Health

    Volume 4, Issue 4, July 2001, Pages: 316–328, Mark J. C. Nuijten, Peter Van Iperen, Cynthia Palmer, Bob J. Van Hilten and Edward Snyder

    Version of Record online : 28 JUN 2008, DOI: 10.1046/j.1524-4733.2001.44037.x

  17. Parkinson's Disease

    Standard Article

    Wiley Handbook of Current and Emerging Drug Therapies

    Published Online : 13 OCT 2006, DOI: 10.1002/9780470041000.cedt084

  18. Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort

    European Journal of Neurology

    Volume 15, Issue 7, July 2008, Pages: 643–648, P. Damier, F. Viallet, M. Ziegler, I. Bourdeix and K. Rerat

    Version of Record online : 10 JUN 2008, DOI: 10.1111/j.1468-1331.2008.02165.x

  19. Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug

    European Journal of Neurology

    Volume 11, Issue 9, September 2004, Pages: 593–606, L. Brusa, A. Bassi, G. Lunardi, E. Fedele, A. Peppe, A. Stefani, P. Pasqualetti, P. Stanzione and M. Pierantozzi

    Version of Record online : 15 SEP 2004, DOI: 10.1111/j.1468-1331.2004.00860.x

  20. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 27, Issue S1, June 2012, Pages: S1–S523,

    Version of Record online : 19 JUN 2012, DOI: 10.1002/mds.25051